Faldaprevir

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Faldaprevir
Accession Number
DB11808
Type
Small Molecule
Groups
Investigational
Description

Faldaprevir has been investigated for the treatment of Chronic Hepatitis C.

Structure
Thumb
Synonyms
Not Available
External IDs
BI-201335 / BI201335
Product Ingredients
IngredientUNIICASInChI Key
Faldaprevir Sodium1494Q15E7Z1215856-44-2JYIOGGWFNHGWMN-CWNXUBRBSA-M
Categories
UNII
958X4J301A
CAS number
801283-95-4
Weight
Average: 869.821
Monoisotopic: 868.246510533
Chemical Formula
C40H49BrN6O9S
InChI Key
LLGDPTDZOVKFDU-XUHJSTDZSA-N
InChI
InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
IUPAC Name
(1R,2S)-1-({[(2S,4R)-4-[(8-bromo-2-{2-[(1-hydroxy-2-methylpropylidene)amino]-1,3-thiazol-4-yl}-7-methoxyquinolin-4-yl)oxy]-1-[(2S)-2-{[(cyclopentyloxy)(hydroxy)methylidene]amino}-3,3-dimethylbutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-2-ethenylcyclopropane-1-carboxylic acid
SMILES
[H][C@@](N=C(O)OC1CCCC1)(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=O)OC1=C2C=CC(OC)=C(Br)C2=NC(=C1)C1=CSC(N=C(O)C(C)C)=N1)C(C)(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Faldaprevir.Approved, Investigational
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Faldaprevir.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Faldaprevir.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Faldaprevir.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Faldaprevir.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Faldaprevir.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Faldaprevir.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Faldaprevir.Approved, Investigational
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Faldaprevir.Approved
BoceprevirThe serum concentration of Faldaprevir can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Faldaprevir.Approved, Investigational
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Faldaprevir.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Faldaprevir.Approved
CarbamazepineThe metabolism of Faldaprevir can be increased when combined with Carbamazepine.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Faldaprevir.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Faldaprevir.Approved, Investigational, Vet Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Faldaprevir is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Faldaprevir.Approved, Investigational, Vet Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Faldaprevir.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Faldaprevir.Approved, Investigational
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Faldaprevir.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Faldaprevir.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Faldaprevir.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Faldaprevir.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Faldaprevir.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Faldaprevir.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Faldaprevir.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Faldaprevir.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Faldaprevir.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Faldaprevir.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Faldaprevir.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Faldaprevir.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Faldaprevir.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Faldaprevir.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Faldaprevir.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Faldaprevir.Approved, Investigational, Vet Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Faldaprevir.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Faldaprevir.Approved
GarlicThe serum concentration of Faldaprevir can be decreased when it is combined with Garlic.Approved, Nutraceutical
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Faldaprevir.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Faldaprevir.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Faldaprevir.Experimental
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Faldaprevir.Approved, Investigational
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Faldaprevir.Experimental, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Faldaprevir.Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Faldaprevir.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Faldaprevir.Approved, Illicit
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Faldaprevir.Approved, Withdrawn
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Faldaprevir.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Faldaprevir.Investigational
PethidineThe risk or severity of adverse effects can be increased when Faldaprevir is combined with Pethidine.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Faldaprevir.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Faldaprevir.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Faldaprevir.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Faldaprevir.Approved
St. John's WortThe metabolism of Faldaprevir can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Faldaprevir.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Faldaprevir is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Faldaprevir.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Faldaprevir.Approved, Investigational
TipranavirThe serum concentration of Faldaprevir can be decreased when it is combined with Tipranavir.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Faldaprevir.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Faldaprevir.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Faldaprevir.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Faldaprevir.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Faldaprevir.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
42601552
PubChem Substance
347828155
ChemSpider
26327117
BindingDB
50336545
ChEMBL
CHEMBL1241348
PharmGKB
PA166128132
HET
L4T
Wikipedia
Faldaprevir
ATC Codes
J05AE13 — Faldaprevir
PDB Entries
3p8n

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentHealthy Volunteers6
1TerminatedTreatmentHealthy Volunteers1
1TerminatedTreatmentImpaired Renal Function1
1WithdrawnTreatmentHealthy Volunteers1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection3
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C (HCV) / Hepatitis C Genotype 1 / Hepatitis C Viral Infection1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C (HCV) / Hepatitis C Genotype 4 / Hepatitis C Viral Infection1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection2
3CompletedTreatmentHepatitis C Viral Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00295 mg/mLALOGPS
logP4.63ALOGPS
logP8.84ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)3.38ChemAxon
pKa (Strongest Basic)1.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area208.85 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity214.32 m3·mol-1ChemAxon
Polarizability88.38 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Valine and derivatives / N-acyl-L-alpha-amino acids / Proline and derivatives / Alpha amino acid amides / Haloquinolines / Anisoles / Pyrrolidinecarboxamides / N-acylpyrrolidines / N-arylamides / 2,4-disubstituted thiazoles
show 17 more
Substituents
Alpha-oligopeptide / N-acyl-alpha amino acid or derivatives / Valine or derivatives / Proline or derivatives / N-acyl-alpha-amino acid / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Haloquinoline / Quinoline / Alpha-amino acid or derivatives
show 38 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:49 / Updated on June 02, 2018 09:46